Drug intelligence / Profile preview

Oxy186

Development stage: Preclinical
Lead developer: MAX BioPharma
Modality: Small Molecules
Administration: Oral

Overview

Oxy186 is a semi-synthetic oxysterol analog being developed by MAX BioPharma as a dual inhibitor of the Hedgehog (Hh) and WNT signaling pathways. These pathways are critical regulators of embryonic development and tissue homeostasis, but their aberrant activation is linked to the initiation and progression of various malignancies, including pancreatic and lung cancers. By simultaneously targeting both pathways, Oxy186 is designed to overcome potential resistance mechanisms associated with single-pathway inhibition. The drug is currently in the preclinical stage of development for indications such as pancreatic cancer and non-small cell lung cancer (NSCLC).

Other names: Oxy186Oxy-186Oxy 186

Targets

LRP5 (Low-density lipoprotein receptor-related protein 5)Zinc finger protein GLI1 transcriptional complex

Beyond the preview

Go deeper on Oxy186.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxy186.

Explore the full profile